Find an expert

Dr. Pratheep Annamalai is a polymer and nanomaterials scientist with a keen interest in engineering materials for sustainable living. He is an Adjunct Senior Research Fellow at the School of Agriculture and Food Sciences. He has extensive expertise in both translational and fundamental research using nanotechnological tools towards sustainability. Currently, he is interested in alternative proteins and valorisation of agricultural crops and food waste into reactive, building blocks for improving the performance and utility of bioproducts. Thematically, his research focuses on

• Food Processing (plant-based food products)
• Bioproducts (from agri-food waste)
• Sustainable building blocks (for advanced materials).

Before joining UQ, Pratheep studied Chemistry in University of Madras, received PhD in Chemistry from University of Pune (India), then went on to work as a postdoctoral researcher on hydrophobic membranes at the Université Montpellier II (France), and on ‘stimuli-responsive smart materials’ at the Adolphe Merkle Institute - Université de Fribourg (Switzerland).

Upon being instrumental in the discovery of ‘spinifex nanofibre nanotechnology’ and establishing Australia’s first nanocellulose pilot-plant, he has been awarded UQ Excellence awards for leadership and industry partnerships for 2019. Recognising his contribution to the nanomaterials, polymer nanocomposites, polymer degradation and stabilisation regionally and globally, he has been invited to serve as a committee member for ISO/TC229-WG2 for characterisation of nanomaterials (2016), a mentor in TAPPI mentoring program (2018), guest/academic editor for various journals (Fibres, Int. J Polymer Science, PLOS One). He has served as a member of the UQ-LNR ethics committee for reviewing the applications (2017-) and a member of the AIBN-ECR committee in 2014.

Prof David Ascher is currently an NHMRC Investigator and Director of the Biotechnology Program at the University of Queensland. He is also Head of Computational Biology and Clinical Informatics at the Baker Institute.

David’s research focus is in modelling biological data to gain insight into fundamental biological processes. One of his primary research interests has been developing tools to unravel the link between genotype and phenotype, using computational and experimental approaches to understand the effects of mutations on protein structure and function. His group has developed a platform of over 40 widely used programs for assessing the molecular consequences of coding variants (>7 million hits/year).

Working with clinical collaborators in Australia, Brazil and UK, these methods have been translated into the clinic to guide the diagnosis, management and treatment of a number of hereditary diseases, rare cancers and drug resistant infections.

David has a B.Biotech from the University of Adelaide, majoring in Biochemistry, Biotechnology and Pharmacology and Toxicology; and a B.Sci(Hon) from the University of Queensland, majoring in Biochemistry, where he worked with Luke Guddat and Ron Duggleby on the structural and functional characterization of enzymes in the branched-chain amino acid biosynthetic pathway. David then went to St Vincent’s Institute of Medical Research to undertake a PhD at the University of Melbourne in Biochemistry. There he worked under the supervision of Michael Parker using computational, biochemical and structural tools to develop small molecules drugs to improve memory.

In 2013 David went to the University of Cambridge to work with Sir Tom Blundell on using fragment based drug development techniques to target protein-protein interactions; and subsequently on the structural characterisation of proteins involved in non-homologous DNA repair. He returned to Cambridge in 2014 to establish a research platform to characterise the molecular effects of mutations on protein structure and function- using this information to gain insight into the link between genetic changes and phenotypes. He was subsequently recruited as a lab head in the Department of Biochemistry and Molecular Biology at the University of Melbourne in 2016, before joining the Baker Institute in 2019 and the University of Queensland in 2021.

He is an Associate Editor of PBMB and Fronteirs in Bioinformatics, and holds honorary positions at Bio21 Institute, Cambridge University, FIOCRUZ, and the Tuscany University Network.

Paul Dennis leads an exciting research group that applies cutting-edge technologies to understand the roles of microorganisms and their responses to environmental change.

He is also a passionate educator and public speaker who advocates for the importance of biological diversity and evidence-based environmental awareness. He has talked about his research on ABC Radio and a range of other media outlets.

His teaching covers aspects of ecology, microbiology, plant and soil science, and climatology. He considers these topics to be of fundamental importance for the development of more sustainable societies and takes pride in helping others to obtain the knowledge and skills they need to build a better future.

Paul's research has taken him to Antarctica, the Amazon Rainforest, high mountains and oceans. The approaches used in his lab draw on a wide range of expertise in molecular biology, ecology, statistics, computer science, advanced imaging and soil science. He applies these skills to a wide-range of topics and systems including plant-microbe interactions, Antarctic marine and terrestrial ecology, biogeography, pollution and human health.

Birgitta Ebert’s research focuses on developing biotechnology concepts to address critical challenges such as pollution, climate change and overexploitation of natural resources.

She specializes in improving microbial catalysts for eco-friendly chemical and material production by leveraging metabolic engineering, synthetic biology, systems analysis, and modelling. Her goal is to create microbial cell factories that convert renewable resources and waste into valuable products, reducing reliance on petrochemicals. She collaborates closely with chemists and chemical engineers to enhance the integration of chemical and biological processes for improved efficiency and sustainability.

Birgitta has a background in Chemical Engineering and a PhD in Systems Biotechnology from TU Dortmund University (Germany). She led a research group in Systems Metabolic Engineering at the Institute of Applied Microbiology at RWTH Aachen University (Germany) from 2012 to 2019. In 2016, she expanded her expertise in Synthetic Biology by joining the Keasling lab at the University of California in Berkeley and the Joint BioEnergy Institute in Emeryville (USA).

Since April 2019, she has been at the Australian Institute for Bioengineering and Nanotechnology at the University of Queensland, applying her expertise to engineer microbial cell factories for fermentation-based manufacturing.

Dr Fred Fialho Teixeira is an architect, media artist and senior lecturer at University of Queensland, School of Architecture, Design and Planning. He has been working in the fields of computational architecture and immersive environments for the last 20 years. He has been awarded the Dean's Fellowship from the University of California and Media Arts and Technology Fellowship where he initiated is PhD on innovative biological-based design strategies at the California Nano Systems Institute. Additionally he co-established and developed an international research program on the studies of Perception of Space in Architecture and Culture and the UQ Visualisation Lab with a focus on the used of immersive technologies and extended realities (VR/AR/XR). With over 50 publications on design methods and research in digital design and fabrication, his research focuses on bio-augmented spaces through the experiential traits of immersive media and spatial computing strategies. He's an alumni of the Architectural Association, School of Architecture (AA) and accredited architect by Royal Institute of British Architects (RIBA) and Portuguese Chamber of Architects (OA) and also practiced for high profile offices such as Zaha Hadid Architects. Through his innovative strategies he designed over 30 projects from which he was internationally awarded within biology, art and architectural domains. Presently his research work on spatial computation combines the use of mixed reality and advanced manufacturing to enable the next generation of built environments.

Memberships

Architectural Association, School of Architecture (UK),Royal Institute of British Architects (UK), Chamber of Architects (PT), Australian Smart Communities Association (AU).

The molecular evolution of cytochrome P450 Enzymes: biological catalysts of unprecedented versatility.

Cytochrome P450 enzymes (CYPs, P450s) especially those responsible for drug metabolism in humans, are the unifying theme of the research in our lab. These fascinating enzymes are catalysts of exceptional versatility, and functional diversity. In humans they are principally responsible for the clearance of a practically unlimited variety of chemicals from the body, but are also critical in many important physiological processes. In other organisms (plants, animals, bacteria, fungi, almost everything!) they carry out an unprecedented range of functions, such as defense, chemical communication, neural development and even pigmentation. P450s are involved in the biosynthesis of an unequalled range of potent, biologically active natural products in microbes, plants and animals, including many antibiotics, plant and animal hormones, signalling molecules, toxins, flavours and fragrances. We are studying how P450s have evolved to deal with novel substrates by reconstructing ancestral precursors and evolutionary pathways, to answer such questions as how did the koala evolve to live on eucalyptus leaves, a toxic diet for most mammals.

The capabilities of P450s are only just coming to be fully recognized and structural studies on P450s should yield critical insights into how enzyme structure determines function. For example, recently we discovered that P450s are present within cells in the Fe(II) form, a finding that has led to a radical revision of the dogma concerning the P450 catalytic cycle, and has implications for the control of uncoupling of P450 activity in cells. Importantly, the biotechnological potential of P450s remains yet to be exploited. All of the specific research themes detailed below take advantage of our recognized expertise in the expression of recombinant human cytochrome P450 enzymes in bacteria. Our group is interested in finding out how P450s work and how they can be made to work better.

Artificial evolution of P450s for drug development and bioremediation: a way of exploring the sequence space and catalytic potential of P450s. The demonstrated catalytic diversity of P450 enzymes makes them the ideal starting material for engineering sophisticated chemical reagents to catalyse difficult chemical transformations. We are using artificial (or directed) evolution to engineer enzymes that are more efficient, robust and specialized than naturally occurring enzymes with the aim of selecting for properties that are commercially useful in the areas of drug discovery and development and bioremediation of pollutants in the environment. The approach we are using also allows us to explore the essential sequence and structural features that underpin all ~12000 known P450s so as to determine how they work.

Synthetic biology of enzymes for clean, green, solar-powered chemistry in drug development, bioremediation and biosensors. We have identified ancestral enzymes that are extremely thermostable compared to their modern counterparts, making them potentially very useful in industry, since they can withstand long incubations at elevated temperatures. They can be used as ‘off the shelf’ reagents to catalyse useful chemistry, such as in in drug discovery and development, fine chemicals synthesis, and cleaning up the environment. Working with drug companies, we are exploring how they can be best deployed in chemical processes and what structural features make them efficient, robust and specialized. We are also immobilizing P450s in virus-like-particles as ‘designer’ reagents that can be recovered from reactions and reused. To make such processes cheaper and more sustainable, we are using photosynthesis to power P450 reactions for clean, green biocatalysis in microalgae.

Biosketch:

After graduating from UQ with first class Honours in Biochemistry, Elizabeth took up a Royal Commission for the Exhibition of 1851 Overseas Scholarship to pursue doctoral work at Oxford University then undertook postdoctoral work at the Center in Molecular Toxicology and Department of Biochemistry at Vanderbilt University School of Medicine with Prof. F.P. Guengerich. She returned to UQ in 1993 to take up a position in Pharmacology and joined the School of Chemistry and Molecular Biosciences in 2009 as a Professor of Biochemistry.

Professor Peter Gray is a pioneer of biotechnology research and development in Australia. In 2003 he was appointed AIBN’s inaugural Director and has since overseen the institute’s growth to 450 people and an annual turnover of $40million. Before joining AIBN, he was Professor and Head of Biotechnology at UNSW.

Professor Gray has held academic positions at University College London and the University of California, Berkeley. He has had commercial experience in the US, working for Eli Lilly and Co and the Cetus Corporation. His research collaborations include groups at Stanford University; the University of California, Berkeley; and the University of British Columbia, Vancouver.

He serves on several boards and government committees. He is on the board of Engineering Conferences International, New York, a group that runs global, multi-disciplinary engineering conferences, many of which have played key roles in developing emerging industry sectors. The conferences include cell culture engineering; vaccine technology; and scale-up and manufacturing of cell-based therapies. Professor Gray also serves on the board of Biopharmaceuticals Australia Pty Ltd, the company established to build a GMP grade biopharmaceuticals manufacturing facility in Brisbane, and has been heavily involved in negotiations that led to DSM Biologics becoming the facility’s operator.

Professor Gray is a Fellow and Vice-President of the Australian Academy of Technological Sciences and Engineering and a Fellow of the Australian Institute of Company Directors. He has chaired, served on organising committees for, and given plenary and keynote addresses at many key international conferences. In 2006 he attracted to Sydney and chaired the International Biotechnology Symposium – the first time a conference in the four-yearly series was held in the southern hemisphere. Professor Gray is a founder and past president of the Australian Biotechnology Association (Ausbiotech).

Professor Gray has graduated more than 60 PhD students from his research group, in fields including secondary metabolite bioprocesses; bioconversion of cellulosic substrates; mammalian cell expression of complex proteins; nanoparticles for drug delivery; and the development of stem-cell based bioprocesses. He has twice been listed by Engineers Australia among the top 100 most influential engineers in Australia, and in 2001 was awarded the Australian Government’s Centenary Medal.

Dr. Wenyi Gu’s early education was conducted in China which include his undergraduate and master’s degrees in veterinary medicine. In 1996, he migrated to Australia and pursued his PhD study in biochemistry & molecular biology at the Australian National University (ANU). After a short period of work at John Curtin Medical School ANU as a junior scientist, he moved to Brisbane in 2001 for his post-doc at the University of Queensland and currently a post-doctoral research fellow at AIBN. He held a Peter Doherty Fellowship (2006-2009) and was further supported by NHMRC to spend 7 months at Harvard University as a visiting fellow in 2008. Since his post-doctoral research he has been working in the area of using RNAi to treat viral diseases and cancers. He also has a strong background in immunology and vaccine development.

BIO:

Noun (n): I am a Professor in polymer processing in Chemical Engineering, a chief investigator in Advanced Materials Processing and Manufacturing (AMPAM) centre, a chief investigator/director of external links of the ARC industrial transformation training centre (ITTC) in bioplastics and biocomposites, a chief investigator in food and beverage accellerator (FaBA).and a chief investigator in the solving plastic waste cooperative research centre (spwCRC).

Verb (v): I work at the translational research interface between universities and industry. Specifically my research involves rheology, processing and product design of bio-based materials, polymers and nanocomposite materials. I lead translational research projects in biopolymers and biofluid platforms for agrifood, biomedical and high-value manufacturing sectors which attract government and industry funding; and produce patents, licences. industrial know-how as well as fundamental papers.

History (h): I have worked in industry (SRI international, Sola Optical, Moldflow), have worked in five cooperative research centres (CRCs -Food Packaging, Sugar Innovation, Polymers, Fighting Food Waste, Solving Plastic Waste), have acquired and managed continuous government and industry research projects since 1994, was heavily involved in the spinoff of Plantic Technologies from the CRC food packaging in 2002 (and ongoing research support with them until 2016), and was involved in the research that led to the TenasiTech (TPU nanocomposite) spinoff from UQ in 2007.I am a fellow of the institute of chemical engineers (IChemE) and a fellow of the Royal Australian Chemical Institute (RACI). I am on the editorial board of the Plastics, Rubbers and Composites, Starch, the Journal of Renewable Materials, Green Materials and Functional Composite Materials-Springer-Nature. I have experience on the boards of the UQ Dow Centre, the UQ RTA Centre, and the UQ-HBIS Sustainable Steel Innovation Centre. I won IChemE Shedden Uhde Award and Prize for excellence in Chemical Engineering (2004), the CRC Sugar innovation award (2008), the CRCPolymers Chairman’s award for research and commercialisation (2011), and have received the CRC Association Technology Transfer Award, twice, in 2002 and 2015.

Research:

Current projects are focused on developing new sustainable and bio-based polymers and biochemicals from formulation through to degradation/disposal, understanding processing of nanostructured polymers, developing smarter biopolymers and materials for biomedical, drug delivery, food and high value applications, understanding rheology and processing of a range of polymer, foods and liquids and is involved in new initiatives in circular plastics.

Teaching and Learning:

My teaching has spanned Introduction to Engineering Design, Engineering Thermodynamics, Polymer Engineering, Process Economics, Research Thesis and Engineering Management. I am developing new courses in Sustainability and the Circular Economy. My overall teaching goal is to be a relevant, well organised, enthusiastic and empathetic enabler of learning using multiple teaching and learning modes, and be highly connected to current industrial practices and cutting edge research.

International links

I have been a visiting or invited professor at ENSICAEN-University, Caen, Normandy, University of Nottingham, Queen’s University Belfast, the University of Strasbourg and Institut national des sciences appliquées (INSA) de Lyon in France. I have strong international collaborations with the US Department of Agriculture, Albany, USA; Colorado School of Mines, USA; AnoxKaldnes, Sweden; University of Bradford, University of Warwick, University of Nottingham, University of Sheffield, UK, SCION, NZ; Michigan State University, USA, and many Australian universities.

Dr. Anthony Halog: A Pioneer in Sustainable Systems and Circular Economy

Dr. Anthony Halog is a leading authority in sustainable systems engineering and circular economy, with over 22 years of post-PhD experience in academia and research. His work focuses on integrating life cycle assessment (LCA), systems thinking, and industrial ecology to advance global sustainability efforts. Dr. Halog has successfully led numerous research projects in industrial ecology and sustainable supply chain management, contributing significantly to the United Nations Sustainable Development Goals (UNSDGs) and Planetary Boundaries frameworks.

His prolific career includes over 125 publications that have been widely cited and referenced in policy documents by international bodies such as the United Nations and the European Union. With a strong commitment to mentoring, Dr. Halog has guided numerous PhD candidates and postdoctoral researchers, fostering the next generation of sustainability experts. Since completing his PhD, he has examined numerous theses from various universities in Australia, North America, Africa, and Asia. His experience also extends to reviewing several grant proposals for prestigious funding bodies, including the National Science Foundation in the USA and European funding schemes.

Dr. Anthony Halog has received numerous fellowships and awards throughout his career. Notably, he was awarded fellowships from prestigious institutions such as the OECD, DAAD, and the Japan Society for the Promotion of Science (JSPS). He has held visiting fellowships across the globe, including in the UK, Germany, Japan, and Saudi Arabia, focusing on areas like Circular Economy, Green Hydrogen Policy, and Life Cycle Assessment. Dr. Halog's accolades also include early career fellowships from NSERC (Canada) and JSPS, along with several international research grants and academic scholarships, reflecting his global recognition in sustainability science and engineering.

Key areas of expertise include circular economy, bioeconomy, LCA, sustainable supply chain management, and the application of operations research and optimization in engineering sustainable systems. Dr. Halog’s interdisciplinary approach and international collaborations have positioned him as a thought leader in transitioning to a low-carbon, circular economy.

I am a Research Fellow and Leader in Pain Relief Innovation at AIBN, UQ. My research interests sit at the interface of drug delivery and the pain field. My overarching research goal is to improve the quality of day to day life of patients suffering from chronic pain, by applying nanotechnology to the development of novel highly effective pain-killer products for improving chronic pain management. I am looking for highly motivated postgraduate students.

I also enjoy volunteering within the academic community, most notably as Head of the SBMS ECR Committee and Treasurer for The Queensland Chinese Association of Scientists and Engineers (QCASE). I am currently serving as guest editor of Pain Research and Management.and JoVE Methods Collection.

Research Interests

My research is focusing on nano-based drug formulation and development to improve chronic pain management. I have a broad and unique background in both pharmacology and drug delivery systems, with specific expertise in the development of novel drug products and testing their analgesic efficacy and safety including pharmacokinetic and pharmacodynamic studies. To date, I have established five different techniques to produce painkiller–loaded nanoparticles and nanofibers aimed at improving pain relief for patients where currently available pain-killers either lack efficacy or produce dose-limiting side-effects. For example, there is a small and very potent peptide that has been on the market as a chemical for over 10 years but which cannot be used as a therapeutic due to its short half-life and poor oral bioavailability. In the form of my nanoparticles, that peptide has the potential to become an oral treatment for improving pain management in patients whose pain is currently poorly alleviated by clinically used pain-killers. I have significant expertise in the use of rodent pain models to assess novel analgesics, and I have received excellent training in conducting research in accordance with the stringent requirements of the Quality Management System (quality accreditations (GLP and ISO17025) from NATA). Together, my knowledge, skills and experience will facilitate the efficient translation of my research from the bench to the clinic.

The current focus of the lab is on the development of drug-products to solve one of the largest unmet medical needs in the pain field through use of sustainable materials. 1) We are developing multifunctional sutures including biodegradable pain relief sutures. 2) We are developing my innovative novel nanoparticles, which deliver innate-immune targeting peptides for the treatment of cancer and cancer-related pain. We are establishing a platform for the development of safe, effective delivery for other small molecule peptide drugs in general to pave their way to clinical trials. 3) Our research also investigates the role of C5a and C3a, estrogen, etc. in the pathogenesis of chronic pain including neuropathic pain, cancer-related pain, low back pain and OA pain.

We work in collaboration with other leading Australian and international researchers to stay at the forefront of the drug delivery systems field and the pain field. We also provide preclinical evaluation of novel compounds and formulations.

Centre for Solar Biotechnology: Prof Ben Hankamer is the founding director of the Solar Biofuels Consortium (2007) and Centre for Solar Biotechnology (2016) which is focused on developing next generation microalgae systems. These systems are designed to tap into the huge energy resource of the sun (>2300x global energy demand) and capture CO2 to produce a wide-range of products. These include solar fuels (e.g. H2 from water, oil, methane and ethanol), foods (e.g. health foods) and high value products (e.g. vaccines produced in algae). Microalgae systems also support important eco-services such as water purification and CO2 sequestration. The Centre is being launched in 2016/2017 and includes approximately 30 teams with skills ranging from genome sequencing through to demonstration systems optimsation and accompanying techno-economis and life cycle analysis. The Centre teams have worked extensively with industry.

Structural Biology: The photosynthetic machinery is the biological interface of microalgae that taps into the huge energy resource of the sun, powers the biosphere and produces the atmospheric oxygen that supports life on Earth. My team uses high resolution single particle analysis and electron tomography to solve the intricate 3D architecture of the photosynthetic machinery to enable structure guided design of high efficiency microalgae cell lines and advanced artificial solar fuel systems.

Dibesh Karmacharya has a Conservation Biology degree from Wayne State College, USA and a PhD on Conservation and Microbiome Genetics from Griffith University, Australia. He worked extensively in the US for Caliper Lifesciences in New Jersey as a research scientist (transgenic animal models). He promoted Genomics and Proteomics technology platforms for GE Healthcare Lifesciences in the US and Canada. He founded the Center for Molecular Dynamics Nepal (CMDN), a wildlife genetics and clinical epidemiology research center and is the Chairman and Executive Director of the Organization. He also founded Intrepid Nepal Pvt. Ltd.-a molecular diagnostics-based Biotechnology Company, and Intrepid Cancer Diagnostics-a leading cancer diagnostic laboratory. He leads several innovative researches in Nepal including building Nepal’s first genetic database of wild tigers through Nepal Tiger Genome Project. He was the Principal Investigator of PREDICT Nepal project-an emerging pandemic threat project. He also founded BIOVAC Nepal Pvt. Ltd. - a vaccine research, development and manufacturing company. He is Wildlife Conservation Society (WCS) Regional Project Coordinator of Pandemic Prevention Leadership Initiative (PPLI). He specializes in One Health and Conservation Genetics.

Dr Li Li is a Senior Research Fellow at Australian Institute for Bioengineering and Nanotechnology. She received her PhD in Chemical Engineering from China University of Petroleum.

In 2007, she joined the University of Queensland (UQ) as a postdoctoral research fellow in the ARC Centre of Excellence for Functional Nanomaterials, working on nanoparticles and nanomaterials for renewable energy production and storage, environment technology and catalysis including hydrogen production and storage, environmental protection, and gas adsorption. In 2011, she was awarded UQ Postdoctoral Fellowship under the supervision of Prof. Zhi Ping (Gordon) Xu, working on engineered nanomaterials in healthcare and environment control. After Postdoctoral Fellowship, she was awarded Advance Queensland Research Fellow in 2016. Her research focuses on design and engineering functional nanomaterials for drug/gene delivery, sustainable release and oral vaccine delivery for human health and animal health management. Since 2011, she has attracted 22+ research funding including Advance Queensland Fellowship (Mid), Queensland smart future fund, UQ Postdoctoral Research Fellowship, 3 UQ grants and 2 international collaboration projects. Moreover, she has a strong linkage with industry partners on the development of functional targeted nano-delivery systems to enhance the health of farm animals.

Professor Stephen Mahler is a Senior Group Leader at the Australian Institute for Bioengineering and Nanotechnology and Director of the Australian Research Council Training Centre for Biopharmaceutical Innovation (CBI), University of Queensland. Professor Mahler is a biotechnologist with a focus on R&D of recombinant-DNA derived protein biopharmaceuticals, drug delivery systems and nanomedicines. Professor Mahler has a record of translational research success and engages extensively with industry associated with the biomedical sciences both nationally and internationally.

Research within CBI covers three thematic research areas; discovery of new biopharmaceuticals, engineering cells for production of protein-based biopharmaceuticals and advanced manufacturing for industrial production. A current research interest is at the interface of the life sciences and materials science, using a synthetic biology approach for creating novel therapeutic entities as well as new systems for drug delivery.

Professor Mahler has a strong interest in education and training and was formerly Head of the Chemical and Biological Engineering Plan at the University of Queensland (2010-2016). Other educational initiatives include development of Masters Programs and a Continuing Professional Development program in the area of biopharmaceuticals. The CPD program is available to stakeholders in the industry, both in Australia and internationally.

Dr Mostafa Kamal Masud is a CCQ Next Generation Cancer Research Fellow at the Australian Institute for Bioengineering & Nanotechnology (AIBN), the University of Queensland (UQ). In 2020, he received his PhD in Medical Biotechnology Diagnostics and Nanobiotechnology from AIBN, UQ. He received his MS and B.Sc. (Hons.) in Chemistry from Shahjalal University of Science and Technology (SUST), Sylhet-3114, Bangladesh. After completing his PhD, he was awarded a prestigious JSPS Postdoctoral Fellowship (success rate >10%) from Japan and served as a Postdoctoral Fellow at Japan's National Institute for Materials Science (NIMS).He recently been awarded a highly prestigious ARC DECRA fellowship for the period 2024-2026 and a QLD Cancer Council fellowship for the period 2024–2028. His research focuses on the development of novel nanostructures and nanodiagnostic technologies to address critical issues in medical diagnosis. As an early career researcher, he has an excellent track record with more than 50 peer-reviewed publications in prestigious and high-impact journals in the area that achieve <2400 citations with an h-index of 26 (Scholar google link: https://bit.ly/2Vtv67l). He has developed new classes of superparamagnetic nanostructures and fabricated novel biosensors for the detection of disease-specific biomolecular targets e.g., for miRNA, DNA, exosome and protein biomarker detection that have proven to be easy and effective, allowing for rapid diagnosis with minimal equipment. He made a major contribution to nanotechnology integrated-analytical and diagnostic fields by providing analytical and technological input as well as developing key collaborations with clinicians and biologists for translational research. His strategy is to create nano-architecture point-of-care diagnostic technology for early diagnosis of cancer that could hopefully lead to a healthy and happier life for humans.

Professor Lars Nielsen is leading the development of experimental and computational tools to analyse and design complex biological systems. His expertise in metabolic modelling and flux analysis is available nowhere else in Australia – and in few labs across the world. Professor Nielsen’s studies of biological systems as diverse as bacteria, baker's yeast, sugarcane, insects and mammals has attracted industrial partnerships with companies including Dow, Metabolix, Amyris, LanzaTech, Boeing, Virgin Australia and GE. These metabolic engineering partnerships have focussed on developing new ways of producing aviation fuel, various materials and bioactives (antibiotics, biopesticides, monoclonal antibodies). Professor Nielsen is also applying system analysis and design approaches to tissue engineering including novel strategies for generating microtissues for drug screening and using stem cells to produce red and white blood cells for transfusion.

International links

Professor Nielsen collaborates with some of the world’s pre-eminent metabolic engineers. A joint project with Prof Sang Yup Lee (KAIST, Korea) enabled several extended mutual visits to explore use of sugar for higher value products. A separate project focused on producing synthetic aviation fuel based on isoprenoids involves Professor Nielsen collaborating with global synthetic biotechnology company Amyris and leading isoprenoid metabolic engineer Professor Jay Keasling, from UC Berkeley. Professor Nielsen has secured $8million since 2006 from industry through research grants with US, European, Japanese, Korean, New Zealand and Australian companies.

Research Interests

• Advanced Drug Delivery and Nanomedicine 1.Advanced drug delivery methods (controlled release dosage forms such as tablets, granules and microspheres) 2. Biomaterials as next generation adjuvant for vaccine delivery 3. Surface modified nanomaterials (Silica, Polymer, Liposomes) 4. Programmable nanoparticales for oral drug delivery and targeting 5. Translocation of nanoparticles after oral drug delivery (In-vitro and In-vivo)

Qualifications

• Master of Pharmaceutical Science, Gujarat University
• Bachelor of Pharmacy, Gujarat University